Understanding the concept of uncertainty in patients with indolent lymphoma

被引:21
|
作者
Elphee, Erin Elizabeth [1 ]
机构
[1] Canc Care Manitoba, Malignant Hematol & Lymphoma Dis Site Grp, Winnipeg, MB, Canada
关键词
D O I
10.1188/08.ONF.449-454
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/Objectives: To review the literature on uncertainty in cancer populations, apply this concept to patients diagnosed with indolent lymphoma, identify sources of uncertainty, and present interventions aimed at assessing and addressing the management of uncertainty. Data Sources: English-language literature related to uncertainty in adult patients with cancer, psychological distress, and non-Hodgkin lymphoma, located through electronic databases PubMed (R) and CINAHL (R), hand searches, and personal contacts. Data Synthesis: Review of the literature revealed that uncertainty is being managed in breast cancer survivors and patients with prostate cancer with watchful waiting or active surveillance. The chronic and incurable nature of indolent lymphoma, coupled with symptoms that are vague and transient, are possible sources of uncertainty in patients diagnosed with lymphoma. Nursing interventions should be aimed at assessing, educating, and supporting patients as they work toward a new view of life that incorporates uncertainty. Conclusions: Literature about the experience of patients diagnosed with lymphoma is lacking. The concept of uncertainty should be recognized by clinicians as an important aspect of living with indolent lymphoma because it is present throughout the disease trajectory and, if left untreated, can have a negative effect on patients' overall quality of life. Implications for Nursing: Uncertainty should become an ongoing component of nursing assessment in patients diagnosed with lymphoma. Further research is needed to support the application of uncertainty theory to this patient population.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 50 条
  • [31] Chemotherapy free treatment of indolent lymphoma
    Casulo, Carla
    Friedberg, Jonathan W.
    HEMATOLOGICAL ONCOLOGY, 2017, 35 : 20 - 24
  • [32] CHROMOSOMAL-ABNORMALITIES IN INDOLENT LYMPHOMA
    SPEAKS, SL
    SANGER, WG
    LINDER, J
    JOHNSON, DR
    ARMITAGE, JO
    WEISENBURGER, D
    PURTILO, D
    CANCER GENETICS AND CYTOGENETICS, 1987, 27 (02) : 335 - 344
  • [33] Copanlisib in heavily pretreated indolent lymphoma
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (11): : E650 - E650
  • [34] Role of checkpoint inhibitors in indolent lymphoma
    Buske, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 256 - 256
  • [35] Histological transformation of indolent (follicular) lymphoma
    Ottensmeier, C
    Mead, G
    ANNALS OF ONCOLOGY, 1996, 7 (08) : 849 - 853
  • [36] How I treat indolent lymphoma
    Gribben, John G.
    BLOOD, 2007, 109 (11) : 4617 - 4626
  • [37] RETREATMENT WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA
    Yamada, Toshiki
    Nakamura, Nobuhiko
    Kitagawa, Jun-ichi
    Kanemura, Nobuhiro
    Goto, Naoe
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Hara, Takeshi
    Tsurumi, Hisashi
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] INDOLENT LYMPHOMA: PRACTICAL CLINICAL APPROACH
    Sahin, Berksoy
    LEUKEMIA RESEARCH, 2017, 61 : S9 - S10
  • [39] Indolent lymphoma. Therapy strategies
    Viardot, A.
    Herfarth, K.
    Dreyling, M.
    ONKOLOGE, 2015, 21 (10): : 936 - 945
  • [40] Indolent lymphoma: the pathologist's viewpoint
    Pileri, SA
    Zinzani, PL
    Went, P
    Pileri, A
    Bendandi, M
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 12 - 18